Büyüme Hormonu Testi Sonuçları: Düşük, Yüksek ve Sonraki Adımlar

Kategoriler
Makaleler
Endokrinoloji Laboratuvar Yorumlama 2026 Güncellemesi Hasta Dostu

A single GH number often says less than patients think. The useful answer usually comes from IGF-1, dynamic testing, symptoms, and the rest of the pituitary panel.

📖 ~10-12 dakika 📅
📝 Yayınlandı: 🩺 Tıbbi olarak gözden geçirildi: ✅ Kanıta Dayalı
⚡ Kısa Özet v1.0 —
  1. Random GH can swing from less than 0.1 ng/mL to well above 10 ng/mL within hours, so one sample rarely diagnoses deficiency or excess.
  2. IGF-1 is usually the better first test because it reflects average GH exposure and is read against age-adjusted lab ranges.
  3. Low growth hormone levels on a random test are often normal physiology; low IGF-1 plus symptoms or pituitary disease is more meaningful.
  4. High growth hormone levels after sleep, exercise, fasting, or stress are common; persistent high IGF-1 raises concern for acromegaly.
  5. Stimulation testing is used for suspected deficiency, and many adult protocols view a stimulated peak below about 3 ng/mL as abnormal, with assay and BMI caveats.
  6. Glucose suppression testing is used for suspected excess; failure to suppress GH below 1.0 ng/mL after 75 g oral glucose is concerning in many assays.
  7. False lows happen with obesity, oral estrogen, liver disease, hypothyroidism, malnutrition, and poorly controlled diabetes because IGF-1 can fall without true pituitary failure.
  8. Next steps after abnormal growth hormone test results usually include repeat review, age-adjusted IGF-1, other pituitary hormones, and sometimes pituitary MRI.

Why a random growth hormone test often gives the wrong impression

A growth hormone test done at random often misleads because GH is released in pulses; a healthy adult can read less than 0.1 ng/mL at 10 a.m. and several ng/mL later the same day. After an abnormal result, most patients need an age-adjusted IGF-1 and then either a stimulation test for suspected deficiency or a 75-g glucose suppression test for suspected excess, not an instant diagnosis. At Kantesti AI, our AI flags this issue early, much like our guide on why high or low ranges can mislead.

Macro view of endocrine serum assay used in a growth hormone test workup
Şekil 1: This figure highlights why the sample itself is only one piece of the story in GH interpretation.

GH secretion is pulsatile, with the biggest bursts during slow-wave sleep and smaller bursts after exercise, stress, fasting, or acute illness. Assay standardization is still imperfect, so a value of 2 ng/mL can look different across labs unless the method is known (Clemmons et al., 2011).

I am Thomas Klein, MD, and I see this weekly: a 34-year-old gets a 'low' GH of 0.2 ng/mL on a routine panel, panics, and turns out to have normal IGF-1 and no pituitary disease. Most patients do better when we step back, review symptoms, and use the same common-sense approach we use for sınırda laboratuvar sonuçları.

The practical takeaway is simple. Low random GH usually means very little, and high random GH can be completely physiologic after a workout or a poor night of sleep; only a consistent pattern plus symptoms moves the needle.

When IGF-1 is the better first test than GH

Age-adjusted IGF-1 is usually the better first test because it reflects average GH exposure over time rather than a 15-minute pulse. Most endocrine clinics order IGF-1 before dynamic testing, and Kantesti's neural network cross-checks it against age, sex, liver markers, and the broader biyobelirteç referans kılavuzu on our AI kan testi analizörü.

3D pituitary-to-liver pathway showing why a growth hormone test needs IGF-1 context
Şekil 2: This figure shows the GH-to-IGF-1 pathway that makes IGF-1 more stable than random GH.

The liver makes most circulating IGF-1 in response to GH. That is why a persistently low IGF-1 can support GH deficiency and a high age-adjusted IGF-1 can point toward acromegaly, although Molitch et al. (2011) note that IGF-1 alone does not prove adult GH deficiency unless other pituitary deficits are already present.

Age matters a lot. An IGF-1 of 145 ng/mL may be comfortably normal for a 58-year-old but unexpectedly low for a 19-year-old, which is why I tell patients never to compare their result with a friend's; the same trap shows up in other endocrine tests like our thyroid hormone panel guide.

IGF-1 can still mislead. Liver disease, undernutrition, untreated hypothyroidism, poorly controlled diabetes, and oral estrogen can all lower IGF-1 without true pituitary failure, while puberty and pregnancy can shift reference intervals upward.

What low growth hormone levels may actually mean

A low growth hormone level on a random lab slip rarely diagnoses anything; the meaningful pattern is low IGF-1 plus symptoms, pituitary risk factors, or a failed stimulation test. In adults, I usually think about this when someone has central weight gain, reduced exercise capacity, low bone density, or a history of pituitary surgery, and many have already had other workups like our fatigue-focused lab list.

Clinical diagram of low growth hormone test interpretation with pituitary and body clues
Şekil 3: This figure focuses on the clinical context that makes a low GH pattern more believable.

Adult GH deficiency is more plausible after pituitary tumor surgery, cranial radiation, traumatic brain injury, subarachnoid hemorrhage, or multiple pituitary hormone deficits. When a patient also has low libido or low morning energy, I often review the broader endocrine picture, including morning testosterone timing rather than blaming GH first.

Children are different. A prepubertal child growing less than 4 to 5 cm per year, falling off prior height percentiles, or showing delayed bone age deserves pediatric endocrine review even if one GH value looks normal because random GH is almost useless in that setting.

Here is the nuance most websites skip: malnutrition and oral estrogen can lower IGF-1 more than patients expect, and obesity can blunt stimulated GH. If body composition or hormone-binding issues are muddying the picture, I sometimes compare related markers the same way we do in our SHBG bağlamı.

When a low IGF-1 is more convincing

An isolated low IGF-1 becomes far more convincing when two or more other pituitary axes are also impaired. In practice, low free T4 plus low testosterone or estradiol with inappropriately low LH or FSH raises pretest probability enough that some endocrinologists move faster toward dynamic testing.

What high growth hormone levels can mean and when acromegaly is the concern

High growth hormone levels are concerning mainly when age-adjusted IGF-1 is elevated and the person has features of acromegaly; a single high GH after sleep, exercise, or fasting is common and often benign. The first extra clue on labs is sometimes another pituitary signal, which is why I also review prolactin patterns.

Hands comparing a tight ring as a clue after abnormal growth hormone test results
Şekil 4: This figure shows one of the subtle real-world clues that can accompany persistent GH excess.

Acromegaly usually comes from a GH-secreting pituitary adenoma. Classic clues are rings or shoes getting tighter, new gap between the teeth, oily skin, sweating, carpal tunnel symptoms, sleep apnea, hypertension, or rising glucose, and the Endocrine Society guideline by Katznelson et al. (2014) still anchors this workup as of April 20, 2026.

Not every person with GH excess looks obviously enlarged. I have seen patients with mild IGF-1 elevation only 1.1 to 1.3 times the upper limit of normal whose biggest complaints were headaches, fatigue, and worsening blood pressure—subtle enough that family photos were more revealing than the exam.

Transient GH elevations happen in puberty, pregnancy, vigorous exercise, fasting, poorly controlled type 1 diabetes, acute illness, and stress. That is why I do not call a person high GH from one random value unless the rest of the picture lines up.

Which stimulation tests are used for suspected deficiency

Suspected adult GH deficiency is diagnosed with a stimulation test, not a random GH draw. The classic test is the insulin tolerance test, buna karşılık glucagon Ve macimorelin are common alternatives; our clinicians on the Tıbbi Danışma Kurulu use these only when symptoms, IGF-1, and pituitary history justify the hassle.

Laboratory setup for stimulation-based growth hormone test with timed endocrine samples
Şekil 5: This figure shows the kind of controlled setup used for provocative GH testing.

During an insulin tolerance test, insulin is given to trigger controlled hypoglycemia, often to a glucose nadir below 40 mg/dL or clear adrenergic symptoms under supervision. GH is usually reported in ng/mL, which is numerically the same as micrograms per liter, and in many adult protocols a peak GH below 3 to 5 ng/mL is suspicious for deficiency, though the exact cutoff depends on assay, BMI, and local standards (Molitch et al., 2011).

The glucagon stimulation test is slower—often 3 to 4 hours—but it avoids deliberate hypoglycemia and is widely used when seizures or coronary disease make ITT a bad idea. Many centers interpret a peak GH below 3 ng/mL as abnormal, while some obesity-adjusted protocols use lower thresholds closer to 1 ng/mL.

The macimorelin test is the least unpleasant in my experience because it is an oral ghrelin-receptor agonist and usually wraps up in about 90 minutes. A peak GH around below 2.8 ng/mL is commonly treated as abnormal in adults, although availability and reimbursement still vary by country.

Preparation matters more than most patients expect. Fasting for 8 to 10 hours, avoiding hard exercise for 24 hours, and reviewing estrogen, glucocorticoid, and diabetes medications can change interpretation; that is one reason Kantesti documents assay context and clinical safeguards in our Tıbbi Doğrulama.

Adequate stimulated peak >5 ng/mL on many adult protocols Severe GH deficiency is unlikely, though assay and BMI still matter.
Borderline response 3-5 ng/mL Interpret with BMI, assay method, symptoms, and pituitary history.
Low stimulated peak 1-3 ng/mL GH deficiency becomes more likely, especially with other pituitary deficits.
Severely blunted peak <1 ng/mL Severe adult GH deficiency is strongly suspected and endocrine follow-up is warranted.

Why BMI changes the cutoff

Obesity physiologically reduces stimulated GH peaks, so a heavier patient can fail an older cutoff without true structural pituitary disease. This is one of those areas where context matters more than the number, and some centers now use BMI-adjusted thresholds to avoid overdiagnosis.

How doctors confirm growth hormone excess with a glucose suppression test

Suspected GH excess is usually confirmed with a 75-g oral glucose suppression test after a high age-adjusted IGF-1. Our endocrine team described on Hakkımızda follows this sequence because normal physiology should suppress GH after glucose, whereas acromegaly does not.

Growth hormone test follow-up using oral glucose suppression setup and timed serum samples
Şekil 6: This figure shows the confirmatory test used when GH excess is suspected.

In most modern assays, GH should suppress to below 1.0 ng/mL after glucose; some highly sensitive platforms use a stricter normal target of below 0.4 ng/mL. When GH stays above these levels and IGF-1 is also high, the probability of acromegaly rises sharply (Katznelson et al., 2014).

This test is not perfect. Poorly controlled diabetes, liver disease, kidney disease, adolescence, pregnancy, and assay drift can blur the result, and some European units use slightly different suppression cutoffs than U.S. labs.

If suppression fails, the next step is usually a pituitary MRI with contrast plus a broader pituitary panel. I also ask about snoring, ring size, headaches, and whether old wedding bands still fit—patients often remember that before they remember when symptoms started.

Appropriate suppression <1.0 ng/mL after 75-g glucose Acromegaly is unlikely in most assay systems.
Tight-assay target <0.4 ng/mL Some modern assays use this lower normal threshold for full suppression.
Equivocal non-suppression 1.0-2.0 ng/mL Repeat testing, assay review, or IGF-1 confirmation may be needed.
Abnormal non-suppression >2.0 ng/mL Persistent GH excess is concerning, especially when IGF-1 is high.

When we repeat the test

I repeat or reframe testing when IGF-1 is only mildly elevated, symptoms are thin, or the sample came from a different assay platform than prior results. That small methodological detail saves a surprising number of unnecessary MRIs.

The common reasons growth hormone test results look falsely low or falsely high

False growth hormone test results are common because GH and IGF-1 respond to physiology, body composition, and assay design. Kantesti AI treats results as low-confidence when the sample follows intense exercise, sleep disruption, fasting, oral estrogen use, or major illness, which is exactly the kind of context Clemmons et al. (2011) argued laboratories should not ignore.

Pituitary lab assay comparison showing why one growth hormone test can vary by method
Şekil 7: This figure emphasizes pre-analytic and analytic reasons that GH and IGF-1 can look abnormal.

A hard workout can transiently raise GH several-fold, and deep sleep can produce the day's largest pulse. I usually tell patients to skip heavy training for 24 hours before dynamic testing and to avoid drawing conclusions from a sample taken right after a night shift.

Obesity tends to blunt stimulated GH responses, while oral estrogen can lower IGF-1 more than transdermal estrogen does because of first-pass liver effects. That is one reason I often review hormone context, especially in women using oral therapy, alongside age-based references such as our estradiol ranges.

Assay variability is real. A GH of 0.7 ng/mL from one platform does not always equal 0.7 ng/mL from another, and high-dose biotin can affect some immunoassays, so serial follow-up should ideally use the same lab and the same method; it is the same philosophy behind a kişiselleştirilmiş bir başlangıç düzeyiyle kontrol etmezse yanlış okunacaktır..

How age, puberty, sex steroids, and body composition change the numbers

Age, puberty, sex steroids, and body fat change GH biology enough that one universal cutoff does not work. The same IGF-1 number can be reassuring in a 65-year-old and concerning in a 15-year-old, which is why pediatric endocrinologists often read GH testing alongside puberty markers like LH.

Pituitary context image explaining how age and puberty reshape growth hormone test ranges
Şekil 8: This figure shows why age and pubertal stage change normal GH-axis expectations.

Puberty drives GH and IGF-1 upward. In adolescents with delayed puberty, some centers use sex-steroid priming before GH stimulation testing so a late-maturing 13-year-old is not mislabeled deficient simply because the axis is immature.

Sex steroids matter in adults too. Oral estrogen can lower IGF-1, and low estrogen or androgen states can change body composition, so I sometimes check the wider reproductive-hormone frame with estradiol reference ranges before overcalling pituitary disease.

Body fat changes interpretation in both directions. People with obesity may show a lower stimulated GH peak even without structural pituitary disease, whereas lean endurance athletes can have brisk pulses; in day-to-day practice, context beats dogma.

Children are not small adults

For children, the best screening tool is often a growth chart, not a lab form. Height velocity over 6 ila 12 ay, bone age, pubertal timing, family height pattern, and chronic illness screening usually tell me more than a single GH measurement.

What to do after abnormal growth hormone test results

After abnormal growth hormone test results, the safest next step is usually repeat interpretation, not self-treatment. As of April 20, 2026, no major guideline recommends diagnosing GH deficiency or acromegaly from one random number, so I start with symptoms, medications, IGF-1, and the original lab method; if you are sorting reports at home, our guide to reading results online safely yardımcı olur.

Patient follow-up scene after abnormal growth hormone test with report folder and endocrine review
Şekil 9: This figure captures the practical next step after an abnormal result: organized follow-up, not panic.

Bring every prior report you have, not just the flagged page. A photo or PDF of the original lab, medication list, supplement list, height and weight history, ring or shoe-size change, and any pituitary history makes the endocrine visit far more productive; our lab PDF upload guide shows what details are most useful.

Ask whether you also need prolactin, TSH and free T4, morning cortisol, LH or FSH, estradiol or testosterone, fasting glucose or HbA1c, liver enzymes, and kidney function. When I review serial endocrine labs, trend data over 6 to 24 months often says more than a single point, which is exactly why I like tracking results over time.

Some things should move faster. New visual loss, severe headaches, rapidly progressive growth change in a child, recurrent hypoglycemia in an infant, or obvious acral enlargement deserve prompt endocrine review and sometimes same-week imaging.

One more blunt point: do not start GH injections, peptide secretagogues, or anti-aging stacks after a low result without specialist input. I have had to clean up several cases where gym-bought peptides distorted testing for weeks and delayed the real diagnosis.

How Kantesti AI helps you interpret a growth hormone test safely

Kantesti AI helps by adding context to a growth hormone test rather than pretending one number is destiny. Upload your report to Try the free demo, and our AI checks GH, IGF-1, thyroid markers, liver function, glucose, sex hormones, and prior trends in about 60 saniyede.

Endocrinology follow-up after a growth hormone test with clinician reviewing pituitary imaging
Şekil 10: This figure reflects the real goal of interpretation: getting the right follow-up, not overreacting to a single number.

Kantesti hizmet verir 2 milyondan fazla kullanıcı karşısında 127'den fazla ülke Ve 75+ dil, ve bizim 2.78T parametreli Health AI works within CE-marked, HIPAA-, GDPR-, and ISO 27001-aligned processes. In practical terms, that means our AI can flag when a low IGF-1 may be better explained by liver dysfunction, oral estrogen, or malnutrition than by the pituitary itself.

We also do something very unglamorous but genuinely useful: our platform tags random GH as a low-reliability datapoint unless there is a paired IGF-1, a dynamic test, or a consistent clinical story. Most patients find that reassurance helpful, especially when the abnormality turns out to be noise rather than disease.

I am Thomas Klein, MD, and this is the advice I give in clinic: pause, verify the assay, look at IGF-1, then test dynamically only if the symptoms and risk factors truly fit. If you want a structured first pass before your appointment, Kantesti can organize the data; your endocrinologist should make the diagnosis.

Sıkça Sorulan Sorular

Rastgele bir büyüme hormonu testi eksikliği teşhis edebilir mi?

Rastgele bir büyüme hormonu testi, GH’nin nabızlar halinde salgılanması ve birkaç saat içinde 0,1 ng/mL’nin altından 10 ng/mL’nin üstüne kadar dalgalanabilmesi nedeniyle nadiren eksikliği veya fazlalığı tanılar. Çoğu endokrinolog, ilk tarama testi olarak yaşa göre düzeltilmiş IGF-1’i kullanır; ardından şüpheli eksiklik durumunda bir stimülasyon testiyle veya şüpheli fazlalık durumunda 75 g’lık glukoz baskılama testiyle doğrular. Tek bir anormal GH değeri tanı olarak değil, bir ipucu olarak değerlendirilmelidir.

Normal bir büyüme hormonu testi sonucu nedir?

Tek bir evrensel olarak her zaman işe yarayan normal rastgele GH değeri yoktur. Birçok erişkin laboratuvarı referans aralıklarını yaklaşık 0 ila 5 ng/mL olarak listeler; ancak sağlıklı kişiler uyku, egzersiz, açlık, stres ve ölçüm (analiz) yöntemine bağlı olarak bu değerin altında ya da üstünde olabilir. Akromegali şüphesi varsa, 75 g oral glukozdan sonra GH’nin birçok testte 1,0 ng/mL’nin altında baskılanması normal kabul edilir; oysa erişkin GH eksikliğinde anlamlı olan değer, resmi bir testte uyarılmış (stimüle) zirve (tepe) değerdir.

Yüksek büyüme hormonu düzeyleri ne anlama gelir?

Yüksek büyüme hormonu düzeyleri, örnek egzersiz sonrası, uyku sırasında, açlık sonrası veya akut bir hastalık sırasında alındıysa tamamen normal olabilir. Yaşa göre düzeltilmiş IGF-1 yüksek olduğunda ve akromegali belirtileri bulunduğunda daha endişe verici hale gelir; örneğin daha büyük yüzük veya ayakkabı numarası, terleme, baş ağrıları, uyku apnesi veya yükselen glukoz. Doğrulama genellikle 75 g’lık oral glukoz baskılama testi gerektirir ve GH baskılanmazsa çoğu zaman pitüiter (hipofiz) MRG gerekir.

Düşük büyüme hormonu seviyeleri ne anlama gelir?

Rastgele yapılan bir testte düşük büyüme hormonu düzeyleri çoğu zaman tek başına hiçbir şey ifade etmeyebilir; çünkü GH salgısı doğal olarak atımlar arasında düşer. IGF-1 düşükse, belirtiler yetişkin GH eksikliğiyle uyumluysa veya kişinin pituiter hastalığı, radyasyon öyküsü, travmatik beyin hasarı ya da diğer bazı pituiter hormon eksiklikleri varsa daha anlamlıdır. Yetişkinlerde, ITT, glukagon veya makimorelin testi sırasında düşük uyarılmış tepe değeri, düşük rastgele GH değerinden çok daha fazla tanısal ağırlık taşır.

Büyüme hormonu testi öncesinde aç kalmalı mıyım?

Rastgele yapılan, gündelik bir GH testi için her zaman açlık şart değildir; ancak dinamik testlerde çoğu laboratuvar, yemek yemeden 8 ila 10 saatlik açlık ister. 24 saat boyunca yoğun egzersizden kaçının ve ağızdan alınan östrojen, steroidler, diyabet ilaçları, peptit takviyeleri ve yüksek doz biotin hakkında klinisyene bilgi verin. Bu ayrıntılar, sonucun kendisi kadar yorumlamayı değiştirebilir.

Anormal büyüme hormonu testi sonuçlarından sonra ne yapmalıyım?

Yorumlamayı, orijinal raporla birlikte yaşa göre düzeltilmiş IGF-1, semptomlar ve ilgili hipofiz hormonlarıyla tekrar edin. Prolaktin, TSH, serbest T4, sabah kortizol, LH veya FSH, estradiol veya testosteron, glukoz ve karaciğer testlerine ihtiyaç olup olmadığını ve MRI (MR) endike olup olmadığını sorun. Görsel değişiklikler, şiddetli baş ağrıları, bebekte hipoglisemi veya ellerin, ayakların ya da yüz özelliklerinin belirgin ve giderek artan şekilde büyümesi varsa acil değerlendirme yapılması mantıklıdır.

Obezite büyüme hormonu testini etkiler mi?

Evet. Obezite, uyarı testleri sırasında GH yükselmesini azaltabilir ve IGF-1’i hafifçe düşürebilir; bu da daha kilolu hastaların, yapısal hipofiz hastalığı olmadan bile sınırda anormal görünmesine yol açabilir. Bu nedenle bazı endokrin merkezleri, özellikle uyarılmış GH pikleri yaklaşık 1 ile 5 ng/mL aralığına düştüğünde, daha düşük BMI’ye göre ayarlanmış kesme değerleri kullanır. Bu aralıktaki bir sonuç, belirtiler, hipofiz öyküsü ve kullanılan testin (analizin) tam türü göz önünde bulundurularak yorumlanmalıdır.

Bugün Yapay Zekâ Destekli Kan Tahlili Analizini Alın

Anlık ve doğru laboratuvar testi analizi için Kantesti’ye güvenen dünya genelindeki 2 milyondan fazla kullanıcıya katılın. Kan testi sonuçlarınızı yükleyin ve saniyeler içinde 15,000+ biyobelirteçlerinin kapsamlı yorumunu alın.

📚 Kaynak Gösterilen Araştırma Yayınları

1

Klein, T., Mitchell, S., & Weber, H. (2026). aPTT Normal Aralığı: D-Dimer, Protein C Kan Pıhtılaşma Kılavuzu. Kantesti Yapay Zeka Tıbbi Araştırma.

2

Klein, T., Mitchell, S., & Weber, H. (2026). Serum Proteinleri Rehberi: Globulinler, Albumin ve A/G Oranı Kan Testi. Kantesti Yapay Zeka Tıbbi Araştırma.

📖 Harici Tıbbi Kaynaklar

3

Molitch ME et al. (2011). Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism.

4

Katznelson L et al. (2014). Acromegaly: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism.

5

Clemmons DR et al. (2011). Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clinical Chemistry.

2 milyondan fazlaAnaliz Edilen Testler
127+Ülkeler
98.4%Kesinlik
75+Diller

⚕️ Tıbbi Uyarı

E-E-A-T Güven Sinyalleri

Deneyim

Hekim liderliğinde laboratuvar yorumlama iş akışlarının klinik incelemesi.

📋

Uzmanlık

Klinik bağlamda biyobelirteçlerin nasıl davrandığına odaklanan laboratuvar tıbbı.

👤

Otorite

Dr. Thomas Klein tarafından yazılmış; Dr. Sarah Mitchell ve Prof. Dr. Hans Weber tarafından gözden geçirilmiştir.

🛡️

Güvenilirlik

Alarmı azaltmaya yönelik net takip yollarıyla kanıta dayalı yorumlama.

🏢 Kantesti LTD İngiltere ve Galler’de kayıtlı · Şirket No. 17090423 Londra, Birleşik Krallık · kantesti.net
blank
Prof. Dr. Thomas Klein tarafından

Dr. Thomas Klein, Kantesti AI'da Baş Tıp Sorumlusu olarak görev yapan, uzmanlık belgesine sahip bir klinik hematologdur. Laboratuvar tıbbında 15 yılı aşkın deneyimi ve yapay zeka destekli tanı alanındaki derin uzmanlığıyla Dr. Klein, en son teknoloji ile klinik uygulama arasındaki boşluğu doldurmaktadır. Araştırmaları biyobelirteç analizi, klinik karar destek sistemleri ve popülasyona özgü referans aralığı optimizasyonuna odaklanmaktadır. Baş Tıp Sorumlusu olarak, Kantesti'nin yapay zekasının 197 ülkeden 1 milyondan fazla doğrulanmış test vakasında ,71 TP3T doğruluk oranına ulaşmasını sağlayan üçlü kör doğrulama çalışmalarına liderlik etmektedir.

Bir yanıt yazın

E-posta adresiniz yayınlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir